- Report
- January 2024
- 182 Pages
Global
From €3994EUR$4,500USD£3,438GBP
- Report
- February 2024
- 75 Pages
Asia Pacific
From €4216EUR$4,750USD£3,629GBP
- Report
- July 2021
- 115 Pages
Global
From €4216EUR$4,750USD£3,629GBP
- Report
- February 2024
- 126 Pages
From €3062EUR$3,450USD£2,636GBP
- Report
- January 2023
- 154 Pages
Global
From €3160EUR$3,560USD£2,720GBP
€3950EUR$4,450USD£3,400GBP
- Report
- June 2021
- 130 Pages
Global
€3990EUR$4,815USD£3,554GBP
- Report
- June 2020
- 464 Pages
Global
From €4349EUR$4,900USD£3,743GBP
- Report
- July 2023
- 98 Pages
Global
From €3500EUR$4,224USD£3,118GBP
- Report
- November 2021
- 545 Pages
Global
From €3550EUR$4,000USD£3,056GBP
- Report
- November 2021
- 1165 Pages
Global
From €5326EUR$6,000USD£4,584GBP
- Book
- October 2020
- 288 Pages
The Cell Free DNA (cfDNA) market is a subset of the genomics industry that focuses on the analysis of circulating DNA fragments in the bloodstream. It is used to detect genetic abnormalities, such as chromosomal aneuploidy, and to monitor cancer progression. cfDNA testing is also used to detect fetal genetic abnormalities during pregnancy.
The cfDNA market is expected to grow rapidly in the coming years, driven by increasing demand for non-invasive prenatal testing and the development of new technologies. The market is also expected to benefit from the increasing availability of cfDNA testing kits and the growing awareness of its potential applications.
Notable companies in the cfDNA market include Illumina, Thermo Fisher Scientific, Qiagen, Natera, and Guardant Health. Show Less Read more
